Last reviewed · How we verify
Dapagliflozin/Sitagliptin
This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels.
This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dapagliflozin/Sitagliptin |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor / DPP-4 inhibitor combination |
| Target | SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the kidney, promoting glucose excretion in urine. Sitagliptin is a DPP-4 inhibitor that prevents degradation of incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and reducing glucagon in response to meals. Together, they provide complementary glucose-lowering effects through distinct mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Nasopharyngitis
- Urinary tract infection
- Hypoglycemia
- Headache
Key clinical trials
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin/Sitagliptin CI brief — competitive landscape report
- Dapagliflozin/Sitagliptin updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI